[HRT and ovarian cancer risk]

Gynecol Obstet Fertil. 2015 Apr;43(4):324-5. doi: 10.1016/j.gyobfe.2015.02.015. Epub 2015 Mar 26.

[Article in French]

Authors

P Lopes¹, F Trémollières², A Gompel³

Affiliations

¹ Service de gynécologie-obstétrique, CHU de Nantes, 38, boulevard Jean-Monnet, 44093 Nantes cedex, France. Electronic address: patrice.lopes@chu-nantes.fr.
² Centre de ménopause, hôpital Paule-de-Viguier, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France.
³ Unité de gynécologie endocrinienne, université Paris Descartes, hôpital Cochin Port-Royal, AP-HP, 53, avenue de l'Observatoire, 75679 Paris cedex 14, France.

PMID: 25819391
DOI: 10.1016/j.gyobfe.2015.02.015

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms
Estrogen Replacement Therapy
Female
Hormone Replacement Therapy
Humans
Ovarian Neoplasms*
Risk Factors
Risk*